683 Capital Management’s Filana Therapeutics FLNA Stock Holding History

683 Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-425,000	Closed	-$1.24M	–	247
2025 Q3	$1.24M	Buy	+425,000	New	+$977K	0.06%	118
2017 Q1	–	Sell	-7,287	Closed	-$29K	–	104
2016 Q4	$29K	Sell	7,287 -58,137	-89%	-$270K	﹤0.01%	105
2016 Q3	$458K	Sell	65,424 -10,737	-14%	-$178K	0.05%	84
2016 Q2	$1.17M	Buy	76,161 +10,857	+17%	+$172K	0.19%	58
2016 Q1	$1.02M	Buy	65,304 +3,571	+6%	+$46.2K	0.18%	50
2015 Q4	$756K	Hold	61,733	–	–	0.1%	84
2015 Q3	$791K	Hold	61,733	–	–	0.12%	74
2015 Q2	$748K	Buy	61,733 +41,947	+212%	+$575K	0.16%	70
2015 Q1	$262K	Hold	19,786	–	–	0.1%	64
2014 Q4	$281K	Buy	+19,786	New	+$343K	0.12%	54
2014 Q2	–	Sell	-22,857	Closed	-$880K	–	60
2014 Q1	$880K	Sell	22,857 -38,153	-63%	-$1.35M	0.34%	45
2013 Q4	$2.08M	Sell	61,010 -10,419	-15%	-$277K	0.59%	39
2013 Q3	$1.36M	Hold	71,429	–	–	0.35%	48
2013 Q2	$1.1M	Buy	+71,429	New	+$1.51M	0.37%	42

Other funds holding FLNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

683 Capital Management's FLNA Position: Q4 2025 in Review

683 Capital Management sold out of Filana Therapeutics (FLNA) in Q4 2025, closing a stake of 425,000 shares — an estimated $1.24M sold.

683 Capital Management first reported a position in FLNA in Q2 2013 and held it in 14 quarters. The position peaked at $2.08M in Q4 2013. 107 funds tracked by Wall St. Rank hold FLNA as of Q4 2025.

683 Capital Management reported no remaining Filana Therapeutics position as of Q4 2025 after selling out during the quarter.
683 Capital Management sold 425,000 Filana Therapeutics shares in Q4 2025, an estimated $1.24M.
683 Capital Management first reported a position in Filana Therapeutics in Q2 2013 and held it in 14 quarters.
683 Capital Management's Filana Therapeutics position peaked at $2.08M in Q4 2013.
107 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2025.

Based on 683 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.